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 Faecal immunochemical tests (FIT) detect haemoglobin in stool; a marker of cancer 
 Australia, Spain, and the UK recommend FIT in primary care 
 In these countries, it is used to triage ‘low risk’ patients 
 Emerging evidence supports FIT in patients with ‘low risk’ abdominal symptoms 






Recently, Faecal Immunochemical Tests (FITs) have been introduced for investigation of 
primary care patients with low-risk symptoms of colorectal cancer, but recommendations vary 
across the world. This systematic review of clinical practice guidelines aimed to determine how 
FITs are used in symptomatic primary care patients and the underpinning evidence for these 
guidelines.  
Methods 
MEDLINE, Embase, and TRIP databases were systematically searched, from 01/11/2008 to 
01/11/2018, for guidelines on the assessment of patients with symptoms suggestive of 
colorectal cancer. Known guideline databases, websites, and references of related literature 
were searched. The following questions were addressed: 1) which countries use FIT for 
symptomatic primary care patients; 2) in which populations is FIT used; 3) what is the cut-off 
level used for haemoglobin in the faeces (FIT); and 4) on what evidence are FIT 
recommendations based. 
Results  
The search yielded 2,433 publications; 25 covered initial diagnostic assessment of patients with 
symptoms of colorectal cancer in 15 countries (Asia n=1, Europe n=13, Oceania n= 4, North 
America n=5, South America n=2). In 3 countries (Australia, Spain, and the UK), FIT was 
recommended for patients with abdominal symptoms, unexplained weight loss, change in 





Few countries recommend FITs in symptomatic patients in primary care, either because of 
limited evidence, or because symptomatic patients are directly referred to secondary care 
without triage. These results demonstrate a clear need for research on FIT in the symptomatic 




Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for around 
10% of all new cancers, and is the second most common cause of cancer death (1). As the 
symptoms of colorectal cancer are often vague and frequently caused by benign conditions, 
selection for investigation can be difficult. As a result, colorectal cancer is often diagnosed at a 
late stage, leaving few curative options (2). Diagnosing CRC at an earlier stage results in better 
treatment options and improved survival (3,4).  
 
The usual investigation for possible CRC is colonoscopy, though imaging procedures such as CT 
colonography, are sometimes used. However, these investigations require patient preparation, 
are performed in secondary care, and are relatively expensive. Given the ubiquity of the 
symptoms of possible colorectal cancer, there is a place for a triage test in primary care to 
identify which patients with apparently low-risk symptoms would benefit from definitive 
investigation and which can be reassured without further investigation. Faecal occult blood 
testing, which assesses the presence of red blood cells in the faeces, has largely fallen out of 
use in symptomatic patients because the false-negative rate was considered unacceptably high. 
In recent years, faecal immunochemical testing (FIT), which assesses the quantity of 
haemoglobin in the faeces, has been introduced for screening, and latterly for use in 
symptomatic patients. It has been endorsed by the UK’s National Institute for Health and Care 
Excellence (NICE) guideline ‘Quantitative faecal immunochemical tests to guide referral for 
colorectal cancer in primary care’ (DG30) as a triage test for patients whose low-risk symptoms 
(defined as a below 3% risk of CRC) do not warrant urgent referral (5). Patients with a positive 
test can be referred and offered urgent investigation through secondary care, usually by 
colonoscopy, and those testing negative can be managed in primary care, without further 
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testing for possible CRC unless symptoms change. The evidence underpinning this 
recommendation was not drawn from primary care population studies; instead, it was almost 
entirely from studies of FIT in screening and secondary care settings and expert opinion (5,6).  
 
The NICE-mandated positive threshold for FIT in the low risk symptomatic primary care 
population is 10 g Hb/g of faeces (5). In screening programmes, thresholds are higher;  
positive predictive values (PPVs) of 4.8% to 5.8% are reported with thresholds of 50 to 80 g 
Hb/g (7,8). PPV varies by age and sex  (9,10). Several studies are ongoing to evaluate FIT in the 
symptomatic primary care population. Outside the UK, FIT is being used in a variety of patient 
groups, including those with low risk symptoms, although in some countries it is specifically 
recommended not to be used.  
 
This study reviewed current worldwide recommendations around the assessment of colorectal 
cancer symptoms to determine how FIT is used to triage patients with symptoms of possible 
colorectal cancer in primary care. The aim was to provide an overview of the current guidelines 
and to discuss the areas of uncertainty and controversy with the specific objectives to 
determine 1) which countries use FIT for symptomatic primary care patients; 2) in which 
populations is FIT used; 3) what is the cut-off level haemoglobin in the faeces (FIT) in different 
countries; and 4) on what evidence are FIT recommendations based. 
 
METHODS 
Search strategy and data sources 
A systematic search of the literature was conducted in MEDLINE (through Ovid), Embase, and 
TRIP database, based on MESH headings and textual synonyms of colorectal cancer (protocol 
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available from authors). The search was limited to guidelines and position or consensus 
statements on initial assessment and diagnosis of possible colorectal cancer in symptomatic 
primary care patients, published between November 2008 and November 2018 (supplementary 
material). Existing guideline databases such as NHS evidence and cancer and gastroenterology 
societies, and Google (supplementary material) were hand searched for additional guidelines 
and consensus statements. Guidelines on population-based screening of asymptomatic 
patients were excluded. Reference lists of identified guidelines and related systematic reviews 
were reviewed (6,11). Discussions with Danish colleagues on the use of FIT in their country led 
to the identification of further relevant literature not picked up in the English language search.  
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Inclusion and exclusion criteria  
Inclusion 
- Guidelines, consensus and position statements 
- Initial assessment of suspected colorectal, bowel, or anal cancer  
- Symptom-led guidelines 
- Screening for colorectal cancer 
- Published in the last 10 years (2008 to current) 
Exclusion 
- Publications focused on only on screening or secondary care assessment 
- Publications singularly aimed at the high-risk population (Lynch syndrome, polyposis 
coli, and genetic mutations and patients with a previous history of CRC). 
 
Study selection 
All current guidelines and consensus or position statements on initial assessment of patients 
presenting with symptoms of possible CRC, published within the last 10 years, were included. 
There were no language restrictions, although only English search terms were used. 
Publications with a focus on screening or secondary care assessment were excluded, as were 
publications singularly aimed at the high-risk population (Lynch syndrome and genetic 
mutations, polyposis coli, and patients with a previous history of CRC). Screening was defined 
as the process of investigating an apparently healthy population for a disease: these are usually 
asymptomatic patients. However, sometimes the term ‘screening’ can be used to mean triaging 
symptomatic patients. Therefore, guidelines using the term ‘screening’ were included in the 
title abstract selection in an attempt to identify those that used the term screening in that way. 
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Title, abstract, and full text selection was performed by SB, MM, and SYM. Data were extracted 
by two out of four researchers (SB, SYM, HW and MM), using a specifically developed template. 
Disagreements were resolved by consensus. Information was gathered on publication 
characteristics (country, year of publication, intended audience and funding body or guideline 
committee). The intended audience was classified in four categories: primary care providers, 
secondary care providers, policy makers, and patients and carers. Papers in languages other 
than English were reviewed by native speakers of those languages; either authors of this paper, 
or their international contacts.  
 
Data relating to FIT recommendations were collated: whether FIT was used in the diagnostic 
pathway of symptomatic patients and the name used for FIT. Guidelines were categorized by 
recommendation for the symptomatic primary care population: FIT recommended, FIT 
mentioned but not recommended, FIT not mentioned, or the guideline specifically 
recommended not to use FIT. In guidelines recommending FIT, data extracted on those 
recommendations included the assay types and cut-off values, actions to be taken for positive 
or negative FIT results, and the evidence underpinning the recommendation (including grade 




As this review aimed to give an overview of FIT use in investigation of symptomatic patients, it 
was deemed unnecessary to assess the rigour of the entire guideline development. Therefore, 




The search, performed in Nov 2018, yielded 2,433 unique publications. One hundred and 
twenty-two full text documents were obtained. Twenty-five documents met the inclusion 
criteria covering the initial investigation of patients with symptoms of possible colorectal cancer 
(Figure 1) (5,12,13,14–20,21–30,31–36).  
 
Guideline characteristics 
The 25 publications were developed in 15 countries across five continents (Asia n=1, Europe 
n=13, Oceania n= 4, North America n=5, South America n=2). One guideline was published in 
2009, and the rest published between 2012 and 2018 (Table 1). Eighteen were published in 
English, three in Spanish, two in French, one in Danish and one in Swedish.  
 
Seventeen guidelines were developed by a national healthcare organization, five by a specialist 
society and three by government ministries. Documents varied in their intended audience and 
scope. Most guidelines covered the entire colon cancer pathway from diagnosis to treatment, 
so targeted all healthcare practitioners involved in cancer diagnosis and treatment (n=23); 
however, two guidelines solely covered the primary assessment of symptomatic patients and 
were targeted at primary care practitioners. Besides healthcare professionals, guidelines were 




Most of the guidelines did not specifically cover FIT for symptomatic patients (n=17): one 
guideline recommended specifically not to use FIT in symptomatic patients (New Zealand)(21). 
Many guidelines recommended FIT in screening (n=8), or discussed FIT replacing faecal occult 
blood testing for population screening (n=5) (Table 1). In Denmark, FIT was recommended for 
use in secondary care for patients with change in bowel habit and a normal sigmoidoscopy(30).  
 
FIT recommendations in symptomatic patients 
FIT was recommended in primary care symptomatic patients in four guidelines, from three 
countries (Australia, Spain, and UK (excluding Scotland)) (5,12,17,19,34,35). Three of these four 
were published in the last two years (Table 2). The oldest guideline, published in Australia in 
2009 and revised in 2013, recommended FIT use for case finding in patients with symptoms, 
without any other specifications(17).  
 
In the three most recent guidelines (2017-2018), FIT was recommended for primary care use in 
patients with low-risk symptoms such as lower gastrointestinal symptoms, unexplained weight 
loss or change in bowel habit (Box 1). The recommended cutoff value to define a positive test 
was 10 g Hb/g of faeces in all recommendations, although this threshold was not underpinned 
by evidence. Assay types recommended were OCSensor, HM-Jackarc, and FOBGold. If FIT was 
positive, primary care clinicians were advised to refer patients urgently to secondary care or 
directly for colonoscopy. Only one guideline specifically advised action if FIT were negative; the 




Although the three recent guidelines were based on extensive literature reviews, FIT 
recommendations were largely based on consensus and expert opinion; there was minimal 
published research evidence for the use of FIT in the symptomatic primary care patient 
population. NICE’s DG30 guideline, solely covering FIT use in primary care symptomatic patients 
was based on an extensive systematic review and health economic study(5). However, the 
evidence supporting these recommendations was mainly based on evidence from secondary 
care, population screening and on expert opinion; only one of nine included papers sampled 




Box 1. Recommendations 
Clinical practice guidelines for the prevention, early detection and management of 
colorectal cancer- Australia (19) 
Immunochemical faecal occult blood testing (iFOBT) is of particular use in the following 
patients:  
 People without overt rectal bleeding 
•  Aged over 50 years with either unexplained weight loss or abdominal pain  
•  Aged under 60 years with either altered bowel habit or anaemia*. 
(Consensus-based recommendation; refers to NICE NG12). 
*Change in bowel habit is considered a high risk symptom in those aged over 60 years 
Clinical practice guideline- Spain (34,37) 
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Diagnosis and prevention of colorectal cancer. Patients with lower gastrointestinal 
symptoms of recent onset who do not meet criteria for referral without delay to a 
specialist service due to high suspicion of CRC (rectal or abdominal mass, rectal bleeding 
or iron-deficiency anaemia) should have a faecal immunochemical test (FIT). 
(Quality of evidence low, strength of recommendation strongly in favour). 
NICE guidelines DG30 (2017)-UK (5) 
FIT should be offered to people without rectal bleeding who have unexplained symptoms 
but do not meet the criteria for a suspected cancer pathway urgent referral outlined in 
NICE's NG12 guideline on suspected cancer. 
(Based on Westwood et al.
 
9 included studies; 8 in specialist care, 1 in primary care – 
higher risk referred patients) 
 
Recommendations in symptomatic patients when not using FIT 
The majority of publications (n=13) gave the same recommendation in patients across a variety 
of (usually high risk) features of possible CRC. These higher risk features included rectal 
bleeding, abdominal or rectal mass, and (unexplained) anaemia. Sometimes this 
recommendation was also made for lower-risk symptoms such as change in bowel habit, 
abdominal pain, and weight loss. These patients were recommended to be referred to 
secondary care, mainly for colonoscopy. 
 
Seven guidelines gave different recommendations for different categories of symptoms (higher 
vs lower risk), sometimes in combination with age (14,16,20,24,26,30,36). In patients with 
highest risk symptoms, referral to secondary care for colonoscopy was recommended. In 
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patients with lower risk symptoms (including symptoms such as loss of appetite, abdominal 
pain, mucoid stool, tenesmus and constipation), a watch and wait policy was recommended, 






FIT may be a useful triage test for primary care patients with low risk symptoms of possible 
colorectal cancer, although most of the evidence for this originates from secondary care or 
population screening studies. However, worldwide guidance for primary care clinicians on the 
use of FIT varies greatly, and FIT is only recommended for primary care symptomatic patients 
in three countries: Australia, Spain, and the UK (excluding Scotland, as NICE recommendations 
do not cover Scotland). These recommendations are based on a systematic review of studies 
that included patients with lower GI symptoms suggestive of colorectal cancer (6). That review 
reported the sensitivity of FIT as 92.1% – 100%, and specificity as 76.6% – 85.5%. Of the 10 
studies included in that systematic review, only one was based in primary care (38), where FIT 
was still performed at the point of referral, rather than to triage referrals.  
 
Interpretation and implications 
Evidence on the value of FIT in patients with low risk CRC symptoms is still emerging (39–41). 
Early studies have suggested that it may be effective in selecting patients for further 
investigation, and also for identifying patients at very low risk of colorectal cancer, who can 
avoid a colonoscopy. Despite this emerging evidence, it will take some time for FIT to be widely 
accepted into guidance and clinical practice, partly due to the length of time it takes for 
evidence to be integrated into practice; some are updated only every 10 years (for example, 
NICE guidance in the UK). For example, the Northern Ireland Cancer Network guidance, 
published in 2012, only included reference to the faecal occult blood test - the commonly used 
test at the time. Differences in healthcare systems and patient perspectives in different 
countries may also be barriers to accepting FIT as a triage test. This could relate to the role of 
primary care in the healthcare system, ease of access to secondary care services or to 
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endoscopy, or how burdened secondary care services are. In some countries, including Australia 
and USA, many people have regular screening colonoscopies above a certain age, regardless of 
symptoms. Even with the potential benefits of FIT over colonoscopy, in terms of patient 
acceptability, and cost-effectiveness, it may be a challenge to implement symptomatic FIT 
testing, at least until an acceptable low false-negative rate is identified among this primary care 
population. Updating medical guidelines is a long and arduous process which happens 
infrequently. The lack of recommendations for FIT may reflect the fact that many of the 
identified guidelines were published before the latest evidence on FIT in symptomatic patients. 
Guidelines that did include FIT were published more recently. The evidence on FIT to date 
comes from heterogenous populations at different stages of the care pathway, with different 
thresholds, and different assays used; this heterogeneity adds to the difficulty in making clear 
recommendations. Future updates may begin to integrate FIT testing for this low-risk CRC 
symptoms group. 
 
It is possible that FIT is being used in countries despite not being mentioned in the national 
guidance; anecdotally we know that this is the case in Sweden and Denmark where FIT is used 
extensively in primary care symptomatic patients but not mentioned in any national guidance 
(personal report).  
 
Strengths and limitations 
This guideline review was not restricted to the English language, and included hand searching 
of international websites and gastroenterology societies: both these aspects are strengths. 
However, the search was based on English terminology, which might have restricted the 
identified publications. Despite that, several non-English language guidelines with English 
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language abstracts were identified with the English search terms used. We were also able to 




The performance of FIT across the spectrum of patients, from asymptomatic to those referred 
to secondary care, has not yet been fully explored. With little evidence to support the use of 
FITs in those with low-risk symptoms of possible CRC (39–41), it is currently recommended in 
only three countries. In addition to the limited research evidence, the lack of recommendations 
for FIT may also be driven by concerns about endoscopy services being overwhelmed by 
referrals of patients with positive FITs if they are used in too broad a primary care group, or by 
healthcare systems not considering FIT necessary, as all symptomatic patients are referred for 
a colonoscopy even at very low levels of risk. The availability of imaging services may drive this, 
as well as local priorities and beliefs about the costs and benefits of diagnostic testing. There 
seems to be no evidence around patient preference for FIT testing against colonoscopy, an 
evidence gap that should be filled.  Despite this, FIT test usage is gaining momentum; repeating 
this review in 5 or 10 years may give a different picture as more evidence of its effectiveness as 
a diagnostic test emerges.  
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Figure 1: PRISMA flow diagram
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Table 1: guidelines identified detailing the investigation of patients with symptoms of possible colorectal cancer 
Country/region 
(reference) 
Name of guideline (date) Developing/endorsing 
body 
Development Target group Recommendation 
Argentina 
(28) 
Guía para equipos de atención 
primaria de la salud - Información 
para la prevención y detección 
temprana del cáncer colorrectal  
[Guide for primary health care teams 
- information for prevention and early 
detection of CRC] (July 2015) 
 
Instituto Nacional del 
Cáncer, Ministerio de 
Salud Presidencia de la 
Nación  
Expert opinion Primary care 
practitioners 
Assessment of symptomatic patients does not 




Clinical practice guidelines for the 
prevention, early detection and 
management of colorectal cancer 
(January 2018) 
 
Cancer Council Australia Not reported Primary and 
secondary care 
practitioners 
FIT recommended to investigate patients with 




Early detection screening and 




Society of Australia 
 
Not reported Primary and 
secondary care 
practitioners 
FIT recommended to investigate patients with 
symptoms of colorectal cancer, described as 
case finding (which is defined as screening 




Diagnostic imaging pathways, 
Colorectal Cancer (Suspected) 
(August 2016) 
Funded by Department 













Colon cancer: diagnosis, treatment 










and patients and 
carers 
 
Assessment of symptomatic patients does not 
mention FIT. Those with qualifying symptoms 
are investigated with history taking, 




ColonCheck Screening guidelines 
(2014) 




Assessment of symptomatic patients does not 






Colon or Rectal cancer pathway 
(September 2014) 













Referral of patients with suspected 
colorectal cancer by family 
physicians and other primary care 
providers (April 2017) 







FIT is specifically not recommended for 
symptomatic patients. Low risk symptoms 
should be treated. High risk symptoms warrant 





Screening Recommendations (April 
2016) 
The Colorectal Cancer 
Referral Expert Panel, 









Assessment of symptomatic patients does not 




Guía Clínica AUGE Cáncer 
colorectal en personas de 15 años y 
más 
["AUGE" Clinical Practice Guidelin 
on Colorectal Cancer in people over 
15 years of age] (2013) 
Subsecretaría de salud 
pública - división de 
prevención y control de 
enfermedades , 













Pakkeforløb for kræft i tyk- og 
endetarm [Guideline for colon and 






Assessment of symptomatic patients does not 
mention FIT, but FIT is recommended for 
secondary care in patients with change in 






Early Colon Cancer (July 2013) European Society for 
Medical Oncology 
(ESMO). Endorsed by 











Assessment of symptomatic patients does not 
mention FIT, but it is recommended for 
screening. Common symptoms should be 





Dépistage et prévention du cancer 
colorectal - Actualisation du 
référentiel de pratiques de lexamen 
périodique de santé (EPS) 
[Screening and prevention of CRC - 
update by EPS] (June 2013) 
 
 




Not described Assessment of symptomatic patients does not 
mention FIT.  Colonoscopy recommended 
when patients have symptoms that raise the 
suspicion of colorectal cancer. 
France 
(32) 
Tumeur maligne, affection maligne 
du tissue lymphatique ou 
hématopoïétique  
Cancer colorectal Adénocarcinome 
[Chronic disease, malignant tumours, 
lymphatic tissue or haematological or 
hematopoietic malignancies, CRC, 
Adenocarcinoma] (January 2012) 
 
Haute Autorité de Santé, 
Institut National du 
Cancer  
Not reported Primary and 
secondary care 
practitioners 
FIT used in screening for colorectal cancer. 
Specific symptoms described that warrant the 
initiation of the colorectal cancer diagnostic 
pathway which involves endoscopy.  
Malaysia 
(20) 
CPG Management of CRC (July 
2017) 
Ministry of Health 













and patients and 
carers 
Assessment of symptomatic patients does not 
mention FIT; screening with FIT is performed 
in primary care. Symptoms that do not qualify 
for referral for colonoscopy should be treated, 
and a referral made if the symptoms have not 
resolved within four weeks.  
New Zealand 
(21) 
Suspected Cancer in Primary Care 
(September 2009) 
New Zealand Guidelines 











Regional Colorectal Cancer Network 
Guidelines for the Management of 
Colorectal Cancer (March 2012) 









Assessment of symptomatic patients does not 
mention FIT – FOB is the recommended test. 
Patients with ‘red flag’ symptoms should be 
referred; those who do not fulfil criteria can 




SIGN 126: Diagnosis and 













Assessment of symptomatic patients does not 
mention FIT.  Watch and wait is 









symptoms. FIT recommended in screening for 
colorectal cancer.  
Scotland 
(14) 
Scottish referral guidelines for 

















Assessment of symptomatic patients does not 
mention FIT. Abdominal and rectal exam 




Diagnostico y prevencion del cancer 
colorectal [Diagnosis and prevention 
of colorectal cancer] (July 2018) 
Asociación Espan ̃ola de 
Gastroenterología 
(AEG), 
Sociedad Espan ̃ola de 
Medicina Familiar y 
Comunitaria (semFyC),   
External funding from 
Norgine. 




FIT recommended to investigate patients with 
low risk symptoms of colorectal cancer, and 




Standardiserat vårdförlopp [Colon 
and rectal cancer. Standardised care 
pathway] (January 2018) 








FIT used in practice for assessing 
symptomatic primary care patients 
(communication with expert) but not 




Quantitative faecal immunochemical 
tests to guide referral for colorectal 
cancer in primary care [DG30] (July 
2017) 
National Institute for 












FIT recommended to investigate patients with 




Suspected cancer: recognition and 
referral [NG12] (July 2017) 
National Institute for 












FIT recommended to investigate patients with 






UK and Ireland 
(16) 
Guidelines for the Management of 
Cancer of the Colon, Rectum and 
Anus - Diagnosis, Investigations and 
Screening. (January 2017) 
The Association of 
Coloproctology of Great 
Britain and Ireland 
(ACPGBI) 







Assessment of symptomatic patients does not 
mention FIT, but FIT is recommended in 
screening for colorectal cancer. 
USA 
(27) 
Colorectal cancer screening: 
Recommendations for physicians and 
patients from the U.S. Multi-Society 
Task Force on Colorectal Cancer 
(July 2017) 
U.S. Multi-Society Task 
Force of Colorectal 
Cancer (MSTF): 




Association, and The 










Assessment of symptomatic patients does not 




Table 2: details included in guidelines that specifically recommend the use of the faecal immunochemical test (FIT) for patients with symptoms suggestive of colorectal cancer. 
Country Guideline Population Recommended 
assays 





Australia Clinical practice 





Patients with symptoms other 
than overt rectal bleeding AND 
• people over 50 years with 
either unexplained weight loss or 
abdominal pain OR 
• people under 60 years with 
either altered bowel habit or 
anaemia. 











To be used for case finding Not reported Not 
reported 
None given None given Not reported 




Patients with lower 
gastrointestinal symptoms of 
recent onset who do not meet 
criteria for urgent  referral to a 
specialist service due to high 
suspicion of CRC (rectal or 





10 µg Hb/g 
of faeces 
Urgent 
referral to the 
specialist 


















tests to guide 
referral for 
colorectal cancer 
in primary care - 
guidance [DG30] 
Patients without rectal bleeding 
who have unexplained symptoms 
but do not meet the criteria for a 
suspected cancer pathway urgent 
referral outlined in NICE's NG12 









None given Westwood 2017 
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